Q4 2024 Lantern Pharma Inc Earnings Call Transcript
Key Points
- Lantern Pharma Inc (LTRN) has made significant progress in its clinical pipeline and AI platform, with three AI-driven drugs advancing into clinical trials at a rapid pace and lower cost.
- The company's LP 300 drug has shown promising preliminary results in the harmonic trial, achieving an 86% clinical benefit rate and a 43% objective response rate in never smoker non-small cell lung cancer patients.
- Lantern Pharma Inc (LTRN) received two FDA fast track designations for LP 184 in glioblastoma and triple negative breast cancer, indicating regulatory validation and potential for expedited clinical development.
- The company's AI platform, RADar, has expanded to over 100 billion oncology-specific data points, enhancing its ability to identify non-obvious relationships and potential combination strategies.
- Lantern Pharma Inc (LTRN) has a strong cash position with $24 million in cash equivalents and marketable securities, providing a runway to fund operations for at least 12 months.
- Lantern Pharma Inc (LTRN) reported a net loss of approximately $20.8 million for the full year 2024, an increase from the previous year's loss of $16 million.
- The company anticipates needing substantial additional funding in the near future to continue its operations and development programs.
- R&D expenses increased significantly, from $11.9 million in 2023 to $16.1 million in 2024, primarily due to research studies and clinical trial support.
- The enrollment in clinical trials has been slower than expected, with dose levels for LP 184 reaching higher than anticipated, extending the timeline for results.
- Lantern Pharma Inc (LTRN) faces challenges in securing partnerships and collaborations, as potential deals often break down over financial and resource allocation issues.
Good afternoon and welcome to our 4th quarter and year-end 2024 earnings call. As a reminder, this call is being recorded and all attendees are in a listen-only mode. We will open the call for questions and answers after our management's presentation. A webcast replay of today's conference call will be available on our website at lantern Parma.com shortly after the call.
Or and year, ended December 31, 2024.
A copy of this release is available through our website at lantern Parma.com, where you will also find a link to the slides management we'll be referencing on today's call.
We would like to remind everyone that remarks about future expectations, performance, estimates, and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1,995. Lantern Pharma cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated. A number of factors could cause actual results to differ materially from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
